DOI:
10.1055/s-00000059
Pneumologie
LinksClose Window
References
Calabrò L, Morra A, Giannarelli D. et al.
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.
Lancet Respir Med 2018;
6: 451-460
DOI: 10.1016/S2213-2600(18)30151-6.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.